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The most abundant immune cell types of the tumor microenvironment macrophages recruited 
tumor-eluted factors. The role of these immune cells in tumor progression, and the interplay 
between tumor and immune cells is an emerging field of research with potential for novel 
treatment strategies. Here, a TIE2 expressing macrophage (TEM) subtype is integrated into a 
virtual tumor model. Within the 2D microenvironment, the TEM will differentiate from an 
extravasated monocyte precursor, congregate around the abluminal side of the vasculature in 
response to a chemoattractant gradient, secrete cytokines which favor differentiation of a 
separate angiogenic macrophage subtype [1]. The effects of macrophage populations on tumor 
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M1     =  tumoricidal macrophage subtype 
M2     =  tumorigenic macrophage suntype 
TEM  =  TIE2-expresseing (angiogenic) macrophage subtype 
TAM  = Tumor-Associated Macrophage 
𝑀𝜙     =   Monocyte (macrophage precursor) 
TAF   =  Tumor Angiogenisis Factor 
Ang2  = Angiopoietin2 
IL-10  = Interleukin 10 
NO     =  Nitric oxide 

















LIST OF TABLES 
 
Table                Page 
TABLE I – MACROPHAGE-ASSOCIATED PARAMETERS……………….…….…....….       9 
TABLE II – CHEMOKINE CHARACTERISTICS……………….……......…..…...…....….       11 
TABLE III – MAIN PARAMETERS AND ASSOCIATED VALUES....…..…...…....……..    12 
TABLE IV – ANGIOGENESIS COEFFICIENTS……………………………………………   14 
TABLE V – MACROPHAGE EFFECTS ON TUMOR GROWTH…………………………    17 
TABLE VI – MACROPHAGE DIFFERENTIATION SCALING COEFFICIENTS………..    18 
TABLE VII – IL-10 CALCULATIONS………………………………………………………   19 
TABLE VIII – MACROPHAGE MOVEMENT SCALING COEFFICIENTS………………    21 
















LIST OF FIGURES 
Figure                Page 
FIGURE 1 – REPRESENTATIVE ASSESSMENT OF TUMOR GROWTH...…………          25 
FIGURE 2 –  MACROPHAGE DISTRIBUTIONS RELATIVE TO TUMOR .…………          26 
FIGURE 3 – M MACROPHAGE RATIOS IN VARIATION 1.……..………...…………         27 
FIGURE 4 –  MACROPHAGE RATIOS IN VARIATIONS 1 AND 3...………...…….....        28 
FIGURE 5 –  INTRATUMORAL VASCULATURE BY VARIATION ………………....        29 
FIGURE 6 –  TUMOR RADII BY VARIATION………...…………………………….....         30 































A. Background on Tumor-Associated Macrophages 
 
The role of tumor-associated macrophages (TAMs) in tumor growth (Guo, 
Buranych et al. 2013, Chanmee, Ontong et al. 2014, Guo, Buranych et al. 2014, Tripathi, 
Tewari et al. 2014) and treatment response (Squadrito and De Palma 2011, De Palma and 
Lewis 2013) has been the subject of increased study in the past several years.  What has 
emerged is that populations of tumor-associated macrophages are diverse in both 
phenotype and lineage (Laoui, Movahedi et al. 2011, Italiani and Boraschi 2014).  While 
an increased presence of macrophages at a tumor lesion site is generally correlated with 
poor prognosis, within the  phenotypic range of TAMs are subtypes that produce various 
and even opposing roles in tumor progression (Chanmee, Ontong et al. 2014) (Roca, 
Varsos et al. 2009). The range of tumorigenic and tumoricidal phenotypes reflects the 
conflicting cues within the tumor environment. While the immune response to tumor 
growth may begin as primarily tumoricidal, with macrophages of the M1 or classically 
activated type targeting tumor cells, cytokines secreted by the tumor exploit  the 
2 
 
relatively fluid phenotype of the TAMs to promote tumor growth and survival (Yuan, 
Hsiao et al. 2015) via the M2 subtype.   
A third, more recently discovered subtype, the TIE-2 receptor expressing 
macrophage (TEM), develops from a distinct monocyte precursor, and displays unique 
and non-redundant behaviors highly relevant to tumoral angiogenesis (De Palma, 
Murdoch et al. 2007, Lewis, De Palma et al. 2007, Venneri, Palma et al. 2007, De Palma, 
Venneri et al. 2008). In particular, the critical role of TEMs in tumor angiogenesis and 
vascular remodeling (De Palma, Murdoch et al. 2007, Lewis, De Palma et al. 2007, 
Venneri, Palma et al. 2007, De Palma, Venneri et al. 2008, Riabov, Gudima et al. 2014, 
Stockmann, Schadendorf et al. 2014) was shown by increased TEM infiltration following 
administration of anti-angiogenic agents (Welford, Biziato et al. 2011) as well as the 
blocking of the angiogenic factor Angiopoietin-2 (ANG2), a TIE2 ligand associated with 
activated endothelial cells. This lead to regression of tumor vasculature and arrested 
tumor progression (Mazzieri, Pucci et al. 2011). 
 
B. Background on Macrophage Subtypes 
 
The M1 extreme of the macrophage activation spectrum is commonly associated 
with inflammatory responses and tumoricidal activity by release of proinflammatory 
cytokines and oxygen species such as nitric oxide (NO), which encourage tumor cell 
apoptosis (Plank and Sleeman 2003) (Edin, Wikberg et al. 2012). Its presence in the 
tumor microenvironment is correlated with reduced angiogenesis required to supply the 
increased tumor metabolic needs, and thus reduced tumor growth and survival (Yuan, 
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Hsiao et al. 2015) (Italiani and Boraschi 2014). The relative proportion of the M1 
macrophages generally decreases with tumor progression. The M1 subtype is identified 
by surface receptors CD14++CD16− (Plank and Sleeman 2003). 
The M2 or alternatively activated macrophages encompass a broader family of 
macrophages involved in tissue healing under normal conditions. Within the tumor 
microenvironment, they are recruited for tumor progression (Chanmee, Ontong et al. 
2014), and generally comprise a larger portion of the TAMs in advanced tumors (Sica 
and Mantovani , Chanmee, Ontong et al. 2014). Hypoxia-induced factors such as VEGF-
A, endothelin-2, and interleukin-10 secreted in the tumor environment encourage 
differentiation towards the M2 phenotype (Murdoch, Giannoudis et al. 2004). Within the 
tumor microenvironment, M2s secrete factors such as TGF-β1 which facilitates cancer 
cell proliferation (Leonard, Curtis et al. 2016) (Italiani and Boraschi 2014), VEGF-A 
which promotes angiogenesis and recruits additional macrophages, and MMP-9 which 
facilitates angiogenesis by degrading the extracellular matrix (Chanmee, Ontong et al. 
2014). The proportion of M2 macrophages in the microenvironment tends to increase 
with tumor progression. The M2 subtype is identified by surface receptors 
CD14dimCD16+ (Italiani and Boraschi 2014). 
TIE2 expressing macrophages (TEMs) are a tumorigenic subtype upregulated in a 
variety of environments where angiogenesis occurs, including tumor lesions (Matsubara, 
Kanto et al. 2013) and for post-ischemic recovery (Patel, Smith et al. 2013). They have 
been found in breast cancer metastatic lymph nodes (Kim, Kang et al.), and in colorectal 
metastases to the liver (Catarinella, Monestiroli et al.).  They can be identified by the 
expression of the TIE2 receptor on their surface which, curiously, is also expressed by 
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blood vessel endothelial cells, where they are integral to angiogenic pathways and 
development (Plank and Sleeman 2003, Matsubara, Kanto et al. 2013). Recent research 
indicates that TEMs are recruited to the tumor microenvironment at an early phase of 
development. There, they are believed to play a pivotal role in tumor neovascular 
development by activating the “angiogenic switch” – a transition that occurs when a 
tumor begins to recruit nearby vasculature to supply its increased metabolic demands (De 
Palma and Naldini 2011).  
 
C. Specific Roles of TEMs 
The chief contribution of TEMs to tumor progression appears to be facilitation of 
angiogenesis through structural and paracrine support. The macrophage’s eponymous 
receptor, TIE2, binds the growth factors angiopoietin 1 and 2. In addition to having a 
direct chemotactic effect on the TEMs (Coffelt, Tal et al. 2010) interactions with 
angiopoietins lead to the upregulation of several factors necessary to angiogenic 
processes, including MMP-9, CTSB, and IL-10, not dissimilar to role of the M2 subtype 
(Coffelt, Tal et al. 2010, Coffelt, Chen et al. 2011). However, TEMs have a more 
multifaceted involvement in angiogenesis (De Palma, Venneri et al. 2008).  In addition to 
upregulating these factors in TEMs, angiopoietin 2 (Ang2) acts as a chemoattractant, 
causing the TEMs to congregate along the abluminal side of vessels (Lewis, De Palma et 
al. 2007). Here, TEMs are thought to directly facilitate vessel sprouting by providing both 
a structural scaffold and paracrine support for endothelial sprouts, aiding in their growth 
(De Palma, Murdoch et al. 2007), and preventing collapse due to the high hydrostatic 
pressure associated with the tumor microenvironment (Matsubara, Kanto et al. 2013).  As 
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a tumor grows and its metabolic needs increase, TEMs continue to fill a supportive role 
in the growth and maturation of the neovasculature that supplies it with nutrients and 
oxygen (Matsubara, Kanto et al. 2013) . In a 2008 study by De Palma et al. comparing a 
tumor model with an intact and TEM-knockout population of tumor associated 
macrophages, the tumors with an intact population showed just under a four-fold increase 
in vascular development in comparison to the TEM-ablated population (De Palma, 
Venneri et al. 2008). 
In addition to their more direct roles in facilitating neovascular development, 
TEMs also contribute to the cocktail of other tumor-friendly cytokines in the 
microenvironment. IL-10 is an immune cytokine secreted from most leukocytes, 
including macrophages, as well as tumor cells themselves (Hamidullah, Changkija et al. 
2012). It has pleiotropic effects in the tumor microenvironment, being implicated in both 
suppression of tumorigenic cytokines such as IL-6 [31], and in improved immune escape, 
poor prognosis, and advanced cancer stage (Kozlowski, Zakrzewska et al. 2003, 
Dehqanzada, Storrer et al. 2007, Esquivel-Velazquez, Ostoa-Saloma et al. 2015, Capone, 
Guerriero et al. 2016). While it is known to be upregulated in several cancer types, 
including breast cancer (Beckebaum, Zhang et al. 2004, Esquivel-Velazquez, Ostoa-
Saloma et al. 2015) a consensus has yet to be reached on whether it is a definitive 
indicator of tumor progression and patient prognosis, as some studies have suggested that 
its overexpression leads to subsequent immune rejection of the tumor (Mocellin, 
Marincola et al. 2005). IL-10 is also known to play a role in inducing infiltrating 
monocytes to adopt the tumorigenic M2 phenotype (Italiani and Boraschi 2014). TIE2-
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expressing macrophages are known to secrete IL-10, and thus may contribute to the 
increased ratio of M2 to M1 macrophages in the tumor microenvironment.  
 
D. Contribution to Previous Models 
Previous mathematical modeling work has explored critical aspects of tumor-associated 
macrophage activity. Owen and Sherratt (Owen and Sherratt 1998, Owen and Sherratt 
1999) presented a model in which macrophages entered the tumor environment to 
selectively target tumor cells. Later models were developed to simulate macrophages 
primed to destroy cancer cells on contact (Byrne, Cox et al. 2004) or by drug delivery 
(Owen, Byrne et al. 2004). In (Webb, Owen et al. 2007) it was shown that effective 
macrophage targeting of hypoxic tumor cells would benefit from non-cell-cycle dependent 
drugs or limited-diffusivity.  In (Owen, Stamper et al. 2011) it was found that the 
combination of conventional and macrophage-based therapies using magnetic 
nanoparticles could be synergistic. In (Chen, Bobko et al. 2014) the role of tumor 
macrophage hypoxia inducible factors (HIFs) in chemotherapy effectiveness was 
evaluated.  Recently, a model exploring the efficacy of nanoparticle albumin-bound-
paclitaxel (nAb-PTX) using macrophages in a multistage vector system as a therapy for 
hypervascularized breast cancer metastases in the liver was developed (Leonard, Curtis et 
al. 2016).   
The interplay of the various monocyte subtypes with the changing tumor 
microenvironment presents a relevant and challenging task which may benefit from a 
systems analysis perspective.  To this end, recent mathematical modeling and 
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computational simulation work (Leonard, Curtis et al.) has evaluated the role of 
macrophages in the tumor microenvironment to gain insight into implications for cancer 
treatment and drug delivery.  In this study, a computational framework to further evaluate 
the role of TEMs in relation to M1 and M2 macrophage phenotypes on the growth of 
















































The computational model builds upon recent work simulating generic tumor-
associated macrophages (TAMs) in a vascularized tumor environment (Leonard, Curtis et 
al. 2016), in which a breast cancer lesion metastasized to the liver was simulated – in an 
microenvironment that is known to favor the recruitment of TAMs (Bocuk, Krause et al. 
2015).  In (Leonard, Curtis et al. 2016),  macrophages were utilized as a drug vector, and 
their performance was evaluated experimentally and via computational simulation. Here, 
we do not assume that drug is vectored by macrophages, and instead focus on the effects 
of various macrophage population subtypes on the tumor lesion progression.   
Briefly, the model is composed of a tumor lesion in a 2D grid of preexisting 
vasculature as previously described (Macklin, McDougall et al. 2009, van de Ven, Wu et 
al. 2012, Wu, Frieboes et al. 2013, Leonard, Curtis et al. 2016).  Two types of 
macrophage subtypes are defined – the M1 and M2. The TEM subtype is added as a third 
population that promotes angiogenesis for tumors in the liver (Matsubara, Kanto et al.). 
Given that the monocytes are not biologically active in the model, a simplifying 
assumption is made that TIE2 expressing macrophage differentiate from the same 
monocyte precursor as the M1 and M2 macrophage subtypes. As the TEM phenotype 
appears in the environment, its effects are modeled as follows: 
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• Increasing differentiation of TIE2 macrophages from a monocyte precursor 
with tumor progression  
• Semi-stochastic movement of TEMs along a chemoattractant gradient (Ang2) 
secreted by the peritumoral vasculature, as well as monocyte attractant from 
the hypoxic regions of the tumor. 
• The protein released by the TEMs is modeled after IL-10 to examine the 
effects of cytokine release in the context of immunomodulatory activity. 
• Increased M2 differentiation in response to TEM-eluted IL-10 in the system 
• Increased angiogenesis and resilience of tumoral neovasculature 
The relevant model parameters are outlined in Table I. 
 
TABLE I 
MACROPHAGE-ASSOCIATED PARAMETERS.   
 
Parameter Description Value Reference 
Physiological Parameters 
% of macrophages per tumor total cells 10% Calibrated to match (Leonard, Curtis 
et al. 2016) 
TEM-driven tumor neovasculature increase ~4-fold (De Palma, Venneri et al. 2008) 
TEM portion of differentiated macrophages 55-70%  (Venneri, Palma et al. 2007) 
M2/M1 ratio in highly metastatic tumors 2.06 (Cui 2013) 
M2/M1 ratio in moderately metastatic tumors 0.77  (Cui) 
    
 
 
A. Tumor Growth 
The tumor growth model is based on Macklin et al. (Macklin, McDougall et al. 
2009) and builds upon (Wu, Frieboes et al. 2013, Leonard, Curtis et al. 2016).  
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Simulation of tumor growth begins with a small lesion in a 2D grid of blood vessels 
representing a regularly-spaced capillary grid. The tumor progression is modeled in 
discrete time increments; the tumor conditions are evaluated, updated, and recorded every 
0.075 days.  Advection of the tumor and advancement of its boundary are subject to 
changes in the microenvironment such as fluid pressure, diffusion of hypoxic proteins 
and other angiogenic factors, and concentration of oxygen, glucose and other vital 
nutrients (here, simplified as oxygen only).  Altogether, the tumor microenvironment may 
be described in four regions based on oxygen and proliferation levels. These are: 
• Necrotic region, ΩN, in which oxygen levels are insufficient for viability. 
• Hypoxic region, ΩH, in which oxygen levels are sufficient for viability but not 
proliferation. 
• Proliferating region, ΩP, in which oxygen levels are sufficient for proliferation. 
• Normal (non-tumoral) tissue.  
Tumor boundary advancement with velocity 𝑉𝑐 through the porous extracellular 
matrix of the surrounding normal tissue is based on Darcy’s law (Macklin, McDougall et 
al. 2009):  
 
𝑉𝑐 =  −𝜇∇𝑃 + 𝜒𝐸∇E     (1) 
 
where μ is tissue mobility, encompassing the roles of cell-cell and cell-matrix adhesion, P 
is oncotic pressure, 𝜒𝐸 is haptotaxis, and ∇E is the density of the extracellular matrix. Cell 
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density in the proliferating region is constrained to a value at or below 70% of the tumor 
volume, with extracellular matrix comprising the remaining volume.  
Via a simplifying assumption of uniform density E in the proliferating tumor 
region, the relationship between velocity change and tumor growth is (Macklin, 
McDougall et al. 2009): 
 
∇ ∙ 𝑉𝑐 = 𝜆𝑝     (2) 
 
where 𝜆𝑝 is the non-dimensionalized net tumor proliferation rate (described below). 
As oxygen falls below the threshold for a proliferation state in regions distant 
from vasculature, hypoxic tissue regions develop and release tumor angiogenic factor 
(TAF) and other factors (see Table II).  
 
TABLE II 
CHEMOKINE CHARACTERISTICS  
Chemokine Function Source MW (Da) Fraction of 
TAF 
Diffusivity 
M1f M1 differentiation 
Proliferating & hypoxic 
tumor cells 
21000 1 
M2f M2 differentiation 
Proliferating & hypoxic 
tumor cells 
18606 3.7606 
IL-10 TEM-eluted factor TEM 18606 3.7606 
T2f TEM differentiation 
Proliferating & hypoxic 
tumor cells 
60179 1 




 TAF diffuses outward through the tumor and into the surroundings, where it 
triggers endothelial cell sprouts in the peritumoral vascular grid. Additionally, TAF 
triggers extravasation of macrophages, analogous to the action of VEGF on macrophage 
recruitment to the tumor (Lewis and Murdoch , Hsu, Poché et al.).  If oxygen falls below 
a vital threshold, necrotic tissue develops within the tumor and degrades.   The tumor 
model main parameters are shown in Table III.  
 
TABLE III 
MAIN PARAMETERS AND ASSOCIATED VALUES 
Parameter Value Reference 
Tumor native mitosis rate 0.5 day-1 Estimated 
Tumor tissue threshold for hypoxia 0.5750 Calibrated to match 
(Leonard, Curtis et al. 
2016) 
Tumor tissue threshold for necrosis 0.5325 Calibrated to match 
(Leonard, Curtis et al. 
2016) 
Oxygen diffusivity  1 (*) (Wu, Frieboes et al. 2013) 
Oxygen transfer rate from vasculature 5 (*) (Wu, Frieboes et al. 2013) 
Oxygen uptake rate by proliferating tumor cells 1.5 (*) (Wu, Frieboes et al. 2013) 
Oxygen uptake rate by hypoxic tumor cells 1.3 (*) (Wu, Frieboes et al. 2013) 
Oxygen uptake rate by tumor microenvironment 0.12 (*) (Wu, Frieboes et al. 2013) 
Oxygen decay rate 0.35 (*) (Wu, Frieboes et al. 2013) 
Note: (*) value is rescaled by the square of the simulation system characteristic length (1 
cm) and divided by the system characteristic time (1 sec) multiplied by the oxygen 







B. Angiogenesis and Vascular Development 
The angiogenesis model, simulating the model by (McDougall, Anderson et al. 2006) and 
based on (Macklin, McDougall et al. 2009, Wu, Frieboes et al. 2013), outlines the 
mechanical and chemical effects of tumor proliferation on the growth, maturation, flow, 
flux, and collapse of the surrounding vasculature. The vasculature is simplified to a grid, 
from which irregular vessels sprout and grow in response to gradients of factors and 
pressures produced by the tumor tissue.  
Each vessel sprout grows semi-stochastically, with the probability of growing in 
four directions weighted by the presence of TAF gradient produced by ΩH. The 
sensitivity of the vascular growth is increased in response to contact with factors secreted 
by the TEMs. The magnitude of this response is tuned to correlate with the four-fold 
increase in vasculature surface area found to result from TEM-eluted factors by De Palma 
et al (De Palma, Venneri et al. 2008).   
The change ∆R in radii R of the vessels are modeled according to pressures 
imposed by the fluid carried within them (Pries, Secomb et al. 1998, McDougall, Anderson et 
al. 2002, McDougall, Anderson et al. 2006, Macklin, McDougall et al. 2009), 
 
∆𝑅 = (𝑆𝑤𝑠𝑠 + 𝑆𝑝 + 𝑆𝑚 − 𝑆𝑠)𝑅      (3) 
 
where 𝑆𝑤𝑠𝑠 is the local wall shear stress stimulus, 𝑆𝑝 is the intravascular pressure 
stimulus, 𝑆𝑚 is the flow carrying hematocrit stimulus, and 𝑆𝑠 is the natural shrinking 
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tendency of the vessel as a result of the properties of the basal lamina. This natural 
shrinking tendency is a constant value 𝑆𝑠 (Pries, Hopfner et al. 2010)  unless the pressure 
PC within the vessel reaches a critical pressure 𝑃𝐶𝑇, at which point the shrinking tendency 
increases proportionally to the pressure with a rate 𝑘𝑝𝑐 to simulate complete vessel 
collapse. Vessels may partially recover if the stress is relieved (Wu, Frieboes et al. 2013):  
 
𝑆𝑠 =  𝑘𝑠                                            𝑖𝑓 𝑃𝐶 ≤ 𝑃𝐶𝑇   (4) 
𝑆𝑠 =  𝑘𝑠+𝑘𝑝𝑐(𝑃𝑐 −  𝑃𝐶𝑇)              𝑖𝑓 𝑃𝐶 > 𝑃𝐶𝑇    (5) 
 
In the model, the effect of TEM proximity at a given location is incorporated to 
provide a protective effect on the neovasculature. Specifically, if a TEM is at an adjacent 
location on the matrix to the blood vessel, 1TEM is 1, and 1TEM is 0 if there is no TEM 
present. The factor 𝑘𝑎𝑏𝑙𝑢𝑚𝑖𝑛𝑎𝑙  has the effect of greatly reducing the natural shrinking 
tendency of the vessel (see Table IV).  The change in radius therefore is  (Macklin, 
McDougall et al. 2009): 





𝑘𝑎𝑏𝑙𝑢𝑚𝑖𝑛𝑎𝑙 Effect of abluminal TEM 10E-5 
Calibrated to match (Lewis, De 
Palma et al. 2007) 
𝑘𝑠 Natural shrinking tendency of the vessel 2.24 (Wu, Frieboes et al. 2013) 





Following (Leonard, Curtis et al. 2016), macrophages are simulated to extravasate 
in proportion to the local concentration of macrophage chemoattractants (e.g., pro-
angiogenic factors), and to preferentially migrate towards tissue regions (e.g., hypoxic 
tissue or vascular sprouts) along the increasing gradient of these chemoattractants.   
 
1. Effects on Tumor Growth 
The effects of macrophage variants M1 and M2 are characterized by the action of 
their associated tumoricidal and tumorigenic nitric oxide (NO) and tumor growth factors, 
respectively.  This is simulated by the M2 subtype favoring tumor growth by lowering 
the oxygen threshold for tissue to become necrotic while the M1 subtype counters this 
effect by secreting NO, which results in tumor tissue death.  
The tumor growth factor secreted by the M2 macrophages achieves a transient 
local lowering of the viable oxygen threshold – the oxygen level below which tumor cells 
die – as follows: 
 
𝑄𝑂𝐿 𝑓 =   𝜆𝑂𝐿 ∙ (1 − 𝑀2𝐺𝐹) ∙ (?̅?𝑂𝐿 −  𝑄𝑂𝐿 𝑖) − 𝜆𝐺𝐹 ∙ 𝑀2𝐺𝐹 ∙ (𝑄𝑂𝐿 𝑖 − 𝑄𝑂𝐿 𝑚𝑖𝑛)   (7) 
 
where 𝑄𝑂𝐿 𝑓 is the final quiescence oxygen level, 𝜆𝑂𝐿 is the recovery rate of 𝑄𝑂𝐿 𝑓  to the 
standard quiescence oxygen level ?̅?𝑂𝐿 , 𝑄𝑂𝐿 𝑖 is the initial quiescence oxygen level, 𝑀2𝐺𝐹  
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is the local presence of M2 growth factor, 𝜆𝐺𝐹 is the M2 growth factor effect rate, and 
𝑄𝑂𝐿 𝑚𝑖𝑛 is the lower bound of the quiescence oxygen level (see Table V) 
In addition to inhibiting tumor death, the presence of the M2 growth factor has a 
positive effect on the proliferating region as follows:       
𝜆𝑀2𝐺𝐹 𝑓 = 𝑀2𝐺𝐹 ∙ 𝑃𝑀2𝐺𝐹 ∙ (0.5 − 𝜆𝑀2𝐺𝐹 𝑖) −  𝜆𝑟𝑒𝑐         (8) 
 
where 𝜆𝑀2𝐺𝐹 𝑓 is the final proliferation rate due to the M2 growth factor, 𝑃𝑀2𝐺𝐹  is the M2 
growth factor proliferation effect, 𝜆𝑀2𝐺𝐹 𝑖 is the initial proliferation rate due to the M2 
growth factor, and 𝜆𝑟𝑒𝑐 is the recovery rate of 𝜆𝑀2𝐺𝐹 to zero (see Table V). 
The NO produced by the M1 subtype is incorporated directly into the proliferation 
term as follows: 
𝜆𝑝 = {
𝑛𝑜𝑛 𝑡𝑢𝑚𝑜𝑟𝑎𝑙:                                                                                                    0
Ω𝑃:                                              (𝜆𝑀 +  𝜆𝑀2𝐺𝐹 ) ∙ 𝐶𝑂2  − 𝑀1𝑁𝑂 ∙ 𝟏𝑀1 − 𝜆𝐴
Ω𝐻:                                                             𝜆𝑀2𝐺𝐹 ∙ 𝐶𝑂2  − 𝑀1𝑁𝑂 ∙ 𝟏𝑀1 − 𝜆𝐴
Ω𝑁 :                                                                                                               − 𝐺𝑁
        (9) 
 
where 𝜆𝑀 is the tumor native mitosis rate, 𝐶𝑂2 is the local oxygen concentration, 𝜆𝐴 is the 
apoptosis rate due to natural tumoral cell death, 𝑀1𝑁𝑂 is the effect of nitric oxide, and 
1𝑀1 is the presence of an M1 macrophage at that location. 𝐺𝑁is the non-dimensionalized 







MACROPHAGE EFFECTS ON TUMOR GROWTH 
?̅?𝑂𝐿 Quiescence oxygen level upper bound 0.5750  
𝑄𝑂𝐿 𝑚𝑖𝑛 Quiescence oxygen level lower bound 0.5325  
𝜆𝑂𝐿 Recovery rate of quiescent oxygen level 0.05(*) (Wu, Frieboes et al. 2013) 
𝜆𝐺𝐹  M2 growth factor effect rate 200(*) (Wu, Frieboes et al. 2013) 
𝑃𝑀2𝐺𝐹  M2 growth factor proliferation effect coefficient 1000 (Wu, Frieboes et al. 2013) 
𝜆𝑟𝑒𝑐 Recovery rate of 𝜆𝑀2𝐺𝐹 to zero 0.1(*) (Wu, Frieboes et al. 2013) 
𝑀1𝑁𝑂 
Effect of nitric oxide coefficient 
1.5 
Calibrated to match (Yuan, Hsiao et 
al. 2015) 
𝐺𝑁 Rate of cell degradation for the necrotic region.  0.3(*) (Wu, Frieboes et al. 2013) 
 
Note: (*) Value is rescaled by the square of the simulation system characteristic length (1 
cm) and divided by the system characteristic time (1 sec) multiplied by the oxygen 
diffusivity (Nugent and Jain) (1 x 10-5 cm2 s-1). 
 
2. Differentiation 
Given the increased ratio of M2/M1 macrophages typical of tumor lesions, the 
role of TEM-produced IL-10 on the ratio of M2/M1 macrophage subtypes is modeled. A 
target range of 0.32-5.23 was used, to match in vitro data for metastatic tumors in the 
liver (Cui 2013). 
As monocyte precursors 𝑀𝜙 extravasate from the vasculature in the tumor region, 
they come into contact with proteins diffusing from the tumor interior and vasculature 
that influence their differentiation. The concentration of factors encouraging 
differentiation of given subtypes, analogous to interleukins and angiopoietins, influences 
the differentiation rate for each subtype modeled. The rate is dependent on the size of the 






𝑀1:                                           𝑘𝑀1 ∙ 𝐶𝑀1𝑓
𝑀2:       𝑘𝑀2 ∙ (𝐶𝑀2𝑓 + 𝑘𝑇2𝑀2 ∙ 𝐶𝐼𝐿−10)
          𝑇𝐸𝑀:                     (𝑘𝑇2 ∙ 𝐶𝑇2𝑓 + 𝑘𝐴𝑛𝑔2𝐶𝐴𝑛𝑔2)
       (10) 
 
where 𝑘𝑀1, 𝑘𝑀2, 𝑘𝑇2 are intensity coefficients tuned to reflect the relative prevalence of 
M1 or M2 differentiating monocytes and TIE2 expressing monocytes infiltrating the 
tumor, 𝐶𝑀1𝑓, 𝐶𝑀2𝑓, 𝐶𝐼𝐿−10, 𝐶𝑇2𝑓 and 𝐶𝐴𝑛𝑔2 are local concentrations of chemokines and 
other factors favorable to M1, M2, or TEM differentiation, and 𝑘𝐴𝑛𝑔2 and 𝑘𝑇2𝑀2 are 
intensity coefficients to tune the effect of Ang2 and Il-10 favoring M2 differentiation, 
respectively.  The values of macrophage-associated variables and coefficients are defined 
in Table VI. 
TABLE VI 
MACROPHAGE DIFFERENTIATION SCALING COEFFICIENTS 
𝑘𝑀1 Differentiation of M1 macrophage 20 (Leonard, Curtis et al. 2016) 
𝑘𝑀2 Differentiation of M2 macrophage 11 (Leonard, Curtis et al. 2016) 
𝑘𝑇2 Differentiation of TEM 1.5 (Venneri, Palma et al. 2007) 
𝑘𝐴𝑛𝑔2 Effect of Ang2 on TEM differentiation 0.95 
Calibrated to match (Venneri, 
Palma et al. 2007, Chanmee, 
Ontong et al. 2014) 
𝑘𝑇2𝑀2 Effect of IL-10 on M2 differentiation 0.055 
Calibrated to match (Venneri, 
Palma et al. 2007) (Cui 2013) 
    
 
The concentration of IL-10 in pg/mL is calculated by treating each pixel in the 
spatial model as a 3-dimensional voxel. Thus, the final concentration for IL-10 in 
simulations with the TEM subtype present are within observed values of 5.6-37 pg/mL 
for breast cancers of various TNM stages (Kozlowski, Zakrzewska et al. 2003). The 
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exception is a model without the M2 subtype, which achieved reduced tumor and 















M1 M2 TEM 8201.43 152598185 0.000253395 0.04 0.00633488 6.3349 
M2 TEM 7867.44 146383870 0.000243076 0.04 0.00607691 6.0769 
M1 TEM 6978.27 129839715 0.000215604 0.04 0.00539010 5.3901 
TEM 8276.8 154000560 0.000255724 0.04 0.00639310 6.3931 
 
 
3. Chemokine Production and Diffusion 
Assuming steady-state conditions, the overall mass balance for a particular 
chemokine C is [62]: 
 
   0 1
C C C
production circulation decayC vesselD C C C       1 1  (11) 
 




circulation , and 
C
decay are the (constant) rates of 
chemokine production, wash-out via circulation, and decay, respectively.   
For all the diffusion equations, as well as the pressure and angiogenic factors, the 
conditions at the boundaries are (zero Neumann condition), where N is the element at the 
boundary (oxygen, pressure, or chemokine). 
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4. Movement  
Monocytes as well as M1 and M2 macrophages migrate through the interstitium 
guided by gradients of oxygen, pressure, and chemoattractants. Movement in one of four 
directions is determined semi-stochastically, similar to the differentiation algorithm 
above. The probability of movement in the x+1 direction is as follows: 
 
𝑃𝑥+1 =  (𝑀𝑂 ∙ ∆𝑂𝑥+1 + 𝑀𝑃 ∙ ∆𝑃𝑥+1 + 𝑀𝐶  ∙ ∆𝐶ℎ𝑒𝑚𝑜𝑥+1)   (12) 
 
where 𝑀𝑂 , 𝑀𝑃 and 𝑀𝐶 are intensity coefficients for the influence of oxygen 
concentration, pressure, and chemoattractant on macrophage movement (see Table), 
and ∆𝑂𝑥+1, ∆𝑃𝑥+1 and ∆𝐶ℎ𝑒𝑚𝑜𝑥+1 are the difference in concentration of the factor of 
interest from the current point to the direction in question. The same calculations are 
made for the remaining three directions in the 2D Cartesian grid. A random number is 
then generated which may fall into the interval calculated for one of these four directions. 
Otherwise, the macrophage remains in place.  
The method of movement for the TEM is also semi-stochastic, but relies upon a 
different chemoattractant – Ang2 gradients secreted by the neovasculature. The 
probability of movement in the x+1 direction is modeled as follows: 
 




where 𝑀𝐴𝑛𝑔2 is the intensity coefficient tuned to scale the response of TEMs to the Ang2 
concentration gradient in each direction. 
TABLE VIII 
MACROPHAGE MOVEMENT SCALING COEFFICIENTS 
𝑀𝑂 Effect of oxygen on macrophage movement 1000 (Leonard, Curtis et al. 2016) 
𝑀𝑃 Effect of oxygen on macrophage movement 500 (Leonard, Curtis et al. 2016) 
𝑀𝐶 Chemotactic macrophage movement 350 (Leonard, Curtis et al. 2016) 
𝑀𝐴𝑛𝑔2 Effect of Ang2 on TEM movement 1000 Calibrated to match (De Palma 
and Naldini 2011) 
    
Note: (*) Value is rescaled by the square of the simulation system characteristic length (1 
cm) and divided by the system characteristic time (1 sec) multiplied by the oxygen 




D. Numerical Methods 
A detailed description of the numerical methods employed in the model is given 
in (Wu, Frieboes et al.) and Macklin (Macklin, McDougall et al.) and their incorporated 
references. The continuous equations governing gradients of oncotic pressure by which 
the tumor advances, as well as diffusion of oxygen, TAF, chemokines, and other factors 
are applied to a discrete 2D Cartesian grid via backward Euler’s method with centered 
finite difference calculations. Discretization  of the change in pressure at the boundary 
between oncotic and normal tissue, an immersed moving boundary with jump boundary 
conditions, is applied by a ghost cell method described in (Macklin and Lowengrub) . 
The resulting discretized equations are then solved to steady state at time steps of 
0.075 days (Wu, Frieboes et al.) according to a nonlinear adaptive Gauss-Seidel iteration 
method (Macklin and Lowengrub , Macklin and Lowengrub) to produce, at each grid 
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location, values for concentrations of diffusible factors, oncotic pressure, and interstitial 
fluid pressure outside the tumor.  
To map the changing curved topology of the boundaries between tumor 
hypoxic/normoxic regions and tumor and normal tissue, the level set method is used.  
The vessel radii calculated at each iteration influence the blood flow, which in turn 
modulates the hematocrit in the angiogenesis component, which affects the extravasation 
of monocytes and oxygen from the vasculature. The monocytes and macrophages in 
(Leonard, Curtis et al.) were originally modeled as point sources of drug. In this instance, 
macrophages do not release active drug into the system, but rather IL-10, M2GF, and 


















The tumor, vascular, and macrophage parameters were calibrated as described 
above.  The single and combined effects of the three macrophage types on tumor growth 
were then evaluated, as described in the following table: 
 
TABLE IX 
SUMMARY OF MACROPHAGE CASES EVALUATED  
Variation 1 Variation 2 Variation 3 Variation 4 Variation 5  Variation 6 Variation 7 Variation 8 
M1  M1 M1   M1  
M2 M2 M2  M2   none 
TEM TEM    TEM TEM  
        
A case to match in vivo macrophage ratios was first run, with all three 
macrophage subtypes present (Variation 1). The other cases then examined the tumoral 
response to other population variants. Variation 2 and 5 represent worst-case subtype 
populations – the tumorigenic subtype M2 or M2 and TEM only, driving unrestrained 
tumor growth. Variation 3 is the TEM-ablated model, utilizing M1 and M2 only. 
Variation 4 is the best-case population, with the tumoricidal subtype M1 only.  
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Variation 6 examined the vascular protective effects of TEM alone without its 
effects on M1 and M2 populations. Variation 4 utilizes the tumoricidal subtype M1 and 
immunomodulatory TEM only. Finally, macrophage activity is entirely absent in 
Variation 8, providing a baseline tumor growth profile. 
Each was observed over a simulated 13.5-day timespan of tumor growth. 
 
A. Interaction with blood vessels  
Following the Ang2 gradient secreted by the neovasculature (Fig. 1, bottom right 
panel), the TEMs in variations 1, 2, 4, and 7 preferentially clustered around angiogenic 
vessels (Fig. 1, middle right panel). Here, they prevented vessel collapse due to the 
increased pressure of the tumor environment (Fig. 1, top middle panel) as expressed in 
Equation 6. 
The extravasation of monocytes and subsequent macrophage differentiation is 
triggered by the release of TAF from the hypoxic interior of the tumor (Fig. 1, bottom left 
panel). This first occurred when the lesion reached 200 µm in diameter (Day 7.35 of 
growth). All four models had the same tumoral and vascular growth pattern until this 
time, whereupon they began to diverge. 
Fig. 1 provides a representative assessment of tumor growth, vascular 
development, macrophage infiltration, and key secreted factors at 13 days post-inception 





FIGURE 1 – REPRESENTATIVE ASSESSMENT OF TUMOR GROWTH 
B. Macrophage ratios  
The effect of the TEM subtype on macrophage differentiation can be observed in 
where the M1 and M2 subtypes are clustered. The M1 subtypes are mostly concentrated 
within the tumor lesion, while the M2 subtypes are in the immediate periphery as a 
consequence of the monocyte contact with IL-10 eluted from TEMs (see Fig.1, top right 
panel, and Fig 2.).  The TEM subtypes cluster around angiogenic vessel sprouts as a 
result of the Angiopoietin2 secreted by the neovasculature.   
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 FIGURE 2 – MACROPHAGE DISTRIBUTIONS RELATIVE TO TUMOR 
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In variation 1, TIE2 expressing macrophages differentiating from the monocyte 
precursors became the majority subset in the tumor environment at 60.1%, matching in 
vivo data . In Variation 3 - M1 and M2 only - the M2/M1 ratio stabilized at 0.85. This 
ratio is half the median ratio for highly metastatic tumors, and within the normal range 
for more benign tumor populations (Cui 2013).  A comparison of the two models shows 
that by modeling an increase in IL-10 in response to the IL-10 secreted by the TEMs, the 
M2/M1 ratio was shifted to 1.71 -  a ratio consistent with more metastatic tumors (Cui 
2013). The proportion of different macrophage types in time is shown in Fig. 3 and 4. 
 
 







































Due to the protective clustering around angiogenic vasculature (see Fig. 1 middle 
right panel), variations with the TEM subtype displayed notably greater vascular 
development compared to the corresponding TEM-absent variations. Comparing 
variations 1 and 3, in which TEM is respectively present and ablated (Fig 5) a 3.81-fold 
increase in tumoral vasculature is observed, consistent with the nearly four-fold increase 























FIGURE 5 –   INTRATUMORAL VASCULATURE BY VARIATION 
 
As expected, variations with the TEM subtype present displayed greater vascular 
growth at the endpoint of the simulation, compared with those which did not. The 
presence of the M2 macrophage also encouraged vascular development, due to the 
increased size of the tumor achieved.  
 
D. Tumor Radius 
The effects of the TIE2 subtype on M1/M2 ratio and angiogenic protection in 









































FIGURE 6 –   TUMOR RADII BY VARIATION 
 
Variation 1 with all three subtypes yielded an 11.9% increase in tumor radius over 
Variation 3, the TEM-ablated model, by the end of the simulation. The TEM-ablated 
variations showed a plateau in growth around Day 10. Variations 2 and 5, with TEM and 
M2, and M2 respectively, exhibited the strongest growth. This growth held steady to the 
end of the simulation, despite the development of hypoxic and necrotic regions within the 
tumor lesion (see Appendix IV). Variation 4, with M1 only, showed the least tumor 
growth, exhibiting a plateau consistent with findings of M1-only in vivo (Yuan, Hsiao et 
al.).   
While all variations achieved a size that at least transiently rendered the interior 
portions hypoxic, only those with the TEM subtype and/or the M2 subtype were able to 































would indicate that the role of TEM in tumor vascularization mitigates an important 
immune-mediated check to unbounded tumoral growth.  
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In this study, mathematical modeling was employed to explore the tumor-
promoting and tumor-inhibiting roles of three major tumor-associated macrophage 
subtypes.   A small metastatic lesion in the liver was simulated, growing in a highly-
vascularized microenvironment, coupling the feedback between the tumor tissue, 
vasculature remodeling, and the macrophage activity.  This work could provide a 
modeling platform for system analysis of the potent and varied effects of the macrophage 
activation spectrum on the tumor microenvironment, and presents the possibility of a 
valuable complement to current cancer therapy design.  Given the ability of tumors to 
educate infiltrating macrophages to a tumorigenic subtype, methods of countering this 
may prevent the tumor from harnessing the body’s most potent effectors of tissue 
remodeling as has been previously suggested (Quatromoni and Eruslanov 2012).  
According to this paradigm, therapies which inhibit all monocytes and 
macrophages that infiltrate the tumor environment would be unideal, as they would fail to 
utilize the inherent tumoricidal activity of M1 macrophages. However, a more finessed 
approach by removal of the phenotypically and developmentally distinct TIE-2 
expressing monocyte may be a more desirable and plausible target. Since this subset is 
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also implicated in the facilitation of cancer metastasis by degrading the ECM and guiding 
metastatic cells to the vasculature (e.g., as observed with breast cancer (Williams, Yeh et 
al. 2016)), blockade of this subtype from the tumor microenvironment may be a valuable 
target for both halting and reversing the metastatic progression of cancer in a patient 
(Venneri, Palma et al. 2007). 
Additionally, the action of the TEM subtype may in part explain the pitfalls that 
have been observed in the use of VEGF inhibitors for tumor therapy (Vasudev and 
Reynolds 2014). In some instances, due to the tendency of inhibited tumoral blood supply 
to lead to increased tumor spread through fragmentation and migration of tumor cells, 
preventing the vasculature from growing towards the tumor could force a more malignant 
and metastatic phenotype, as has been observed experimentally (Rubenstein, Kim et al. 
2000, Kunkel, Ulbricht et al. 2001, Lamszus, Kunkel et al. 2003, Pennacchietti, Michieli 
et al. 2003, Stockmann, Doedens et al. 2008, Ebos, Lee et al. 2009, Paez-Ribes, Allen et 
al. 2009, de Groot, Fuller et al. 2010), clinically (de Groot, Fuller et al. 2010, Sharpe, 
Stewart et al. 2013), and predicted by mathematical modeling (Cristini, Lowengrub et al. 
2003, Cristini, Frieboes et al. 2005, Frieboes, Zheng et al. 2006, Wise, Lowengrub et al. 
2008, Frieboes, Jin et al. 2010, Lowengrub, Frieboes et al. 2010).  
Given that TEMs differentiate from a monocyte precursor distinct from the M1 
and M2 subtypes, the possibility of TEM-specific therapies presents a promising method 
of fine-tuning the immune system’s innate defense mechanisms without preventing the 
action of tumoricidal subtypes (Mantovani and Allavena 2015). This would educate the 
tumor to a more benign phenotype, rather than allowing it to alter the immune response to 








Future work will explore the interaction of tumor and macrophage effects during 
treatment.  Therapy could be delivered systemically as free drug or encapsulated in 
nanovectors, as previously simulated (Wu, Frieboes et al. 2014, Curtis, Wu et al. 2015, 
Curtis, England et al. 2016, Curtis, van Berkel et al. 2017), or its delivery to the tumor 
site could be targeted by tumor-associated macrophage uptake and release (Leonard, 
Curtis et al. 2016).  Pharmaceutical ablation of tumor-promoting subtypes while 
supporting tumor-inhibiting phenotypes could provide further therapeutic options.   
The combination of various modalities could be explored via the modeling 
framework presented herein, as such options would be difficult to evaluate solely through 
experimental observation.  With input of patient tumor-specific information, such as size, 
vascularization, and macrophage density, this framework may in the longer term be of 
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